Analysis of the Association between SNCA Polymorphisms and the Risk of Multiple System Atrophy
Objective: To assess the impact of twenty-one single nucleotide polymorphisms (SNPs) located in different regulatory regions of the SNCA gene on the risk of developing…A Phase 2 Study of Risvodetinib in Untreated Parkinson’s Disease
Objective: Risvodetinib was evaluated in a randomized, double-blind, placebo controlled Phase 2 trial at three doses to determine the safety and tolerability in patients with…Novel Insights into the Association Between Parkinson’s Disease and Constipation: Role of SHMT2 as a Promising Biomarker
Objective: This study aims to analyze the shared molecular pathways between Parkinson’s disease (PD) and constipation through integrative bioinformatics methodologies and further validate candidate biomarkers…Novel Usage of Alpha Synuclein as a Biomarker for Screening Parkinson’s disease at Komfo Anokye Teaching Hospital in Ghana
Objective: This study aimed to assess the use of alpha-synuclein as a biomarker for PD screening and investigate its correlation with disease severity. Background: The…Complement C4 Exacerbates Inflammation and Neuronal Damage in Vivo
Objective: To investigate the specific effects of the core complement component C4 on α-synuclein aggregation and neuroinflammation during the pathogenesis of PD. Background: Synucleinopathies are…Case Report of an 82 Year Old Man with an 18 Year History of REM Sleep Behavior Disorder and Colonic Lewy Pathology
Objective: To report a case of an 82-year-old man with a long-standing history of REM sleep behavior disorder (RBD) and colonic Lewy pathology without significant…Alpha Synuclein Seeding Activity Drives Disease Heterogeneity in an Animal Model of Multiple System Atrophy
Objective: To examine the impact of multiple system atrophy (MSA) brain-derived alpha synuclein (αSyn) with diverse seeding activities in an inoculation-based animal model. Background: We…PADOVA: Topline results from a Phase IIb study of prasinezumab in early-stage Parkinson’s disease participants on stable symptomatic treatment
Objective: To evaluate the effect of prasinezumab on slowing down disease progression in participants with early-stage Parkinson’s disease (PD) on stable symptomatic medication. Background: Prasinezumab…Monitoring Parkinson’s Disease in the Dental Chair
Objective: Our goal is to bridge the mechanistic knowledge gap on the Microbiota-Gut-Oral-Brain-Axis (MGOBA)’s role in Parkinson’s disease (PD) pathogenesis through a case-control, proof-of-concept, observational…Alpha-Synuclein Preformed Fibrils Increase the Frequency of CXCR3+ B-cells in Early-stage Parkinson’s Disease Patients
Objective: To investigate the effect of a-Syn Preformed Fibrils (PFF) on CXCR3 expression on B-cells in Parkinson’s Disease (PD) patients at early (E-PD, diagnosed less…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- 6
- …
- 60
- Next Page »